175 related articles for article (PubMed ID: 32557844)
1. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer.
van Steenhoven JEC; Kuijer A; Kornegoor R; van Leeuwen G; van Gorp J; van Dalen T; van Diest PJ
Histopathology; 2020 Oct; 77(4):579-587. PubMed ID: 32557844
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ.
Bosch DE; Kilgore MR; Schmidt RA; Swanson PE; Rendi MH; Chang OH
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):543-547. PubMed ID: 28885232
[TBL] [Abstract][Full Text] [Related]
4. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
[TBL] [Abstract][Full Text] [Related]
5. Phosphohistone H3 (PHH3) as a surrogate of mitotic figure count for grading in meningiomas: a comparison of PHH3 (S10) versus PHH3 (S28) antibodies.
Puripat N; Loharamtaweethong K
Virchows Arch; 2019 Jan; 474(1):87-96. PubMed ID: 30267302
[TBL] [Abstract][Full Text] [Related]
6. Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.
Duregon E; Cassenti A; Pittaro A; Ventura L; Senetta R; Rudà R; Cassoni P
Neuro Oncol; 2015 May; 17(5):663-9. PubMed ID: 25646026
[TBL] [Abstract][Full Text] [Related]
7. The value of phosphohistone H3 as a proliferation marker for evaluating invasive breast cancers: A comparative study with Ki67.
Kim JY; Jeong HS; Chung T; Kim M; Lee JH; Jung WH; Koo JS
Oncotarget; 2017 Sep; 8(39):65064-65076. PubMed ID: 29029412
[TBL] [Abstract][Full Text] [Related]
8. Luminal A versus luminal B breast cancer: MammaTyper mRNA versus immunohistochemical subtyping with an emphasis on standardised Ki67 labelling-based or mitotic activity index-based proliferation assessment.
Finsterbusch K; Decker T; van Diest PJ; Focke CM
Histopathology; 2020 Apr; 76(5):650-660. PubMed ID: 31846096
[TBL] [Abstract][Full Text] [Related]
9. Scoring the percentage of Ki67 positive nuclei is superior to mitotic count and the mitosis marker phosphohistone H3 (PHH3) in terms of differentiating flat lesions of the bladder mucosa.
Gunia S; Kakies C; Erbersdobler A; Koch S; May M
J Clin Pathol; 2012 Aug; 65(8):715-20. PubMed ID: 22554964
[TBL] [Abstract][Full Text] [Related]
10. The Utility of Phosphohistone H3 (PHH3) in Follicular Lymphoma Grading: A Comparative Study With Ki-67 and H&E Mitotic Count.
Khieu ML; Broadwater DR; Aden JK; Coviello JM; Lynch DT; Hall JM
Am J Clin Pathol; 2019 May; 151(6):542-550. PubMed ID: 30788495
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer.
Klintman M; Strand C; Ahlin C; Beglerbegovic S; Fjällskog ML; Grabau D; Gudlaugsson E; Janssen EA; Lövgren K; Skaland I; Bendahl PO; Malmström P; Baak JP; Fernö M
PLoS One; 2013; 8(12):e81902. PubMed ID: 24324728
[TBL] [Abstract][Full Text] [Related]
12. Improving mitotic cell counting accuracy and efficiency using phosphohistone-H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading.
Ibrahim A; Toss MS; Makhlouf S; Miligy IM; Minhas F; Rakha EA
Histopathology; 2023 Feb; 82(3):393-406. PubMed ID: 36349500
[TBL] [Abstract][Full Text] [Related]
13. The potential value of phosphohistone-h3 mitotic index determined by digital image analysis in the assessment of pancreatic endocrine tumors in fine-needle aspiration cytology specimens.
Draganova-Tacheva R; Bibbo M; Birbe R; Daskalakis C; Solomides C
Acta Cytol; 2013; 57(3):291-5. PubMed ID: 23635399
[TBL] [Abstract][Full Text] [Related]
14. Validation of mitosis counting by automated phosphohistone H3 (PHH3) digital image analysis in a breast carcinoma tissue microarray.
Dessauvagie BF; Thomas C; Robinson C; Frost FA; Harvey J; Sterrett GF
Pathology; 2015 Jun; 47(4):329-34. PubMed ID: 25938351
[TBL] [Abstract][Full Text] [Related]
15. Digital Image Analysis of the Proliferation Markers Ki67 and Phosphohistone H3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Accuracy of Grading Compared With Routine Manual Hot Spot Evaluation of the Ki67 Index.
Lea D; Gudlaugsson EG; Skaland I; Lillesand M; Søreide K; Søreide JA
Appl Immunohistochem Mol Morphol; 2021 Aug; 29(7):499-505. PubMed ID: 33758143
[TBL] [Abstract][Full Text] [Related]
16. Improving precise counting of mitotic cells in mantle cell lymphoma using phosphohistone H3 (PHH3) antibody.
Medani H; Elshiekh M; Naresh KN
J Clin Pathol; 2021 Oct; 74(10):646-649. PubMed ID: 32873701
[TBL] [Abstract][Full Text] [Related]
17. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
[TBL] [Abstract][Full Text] [Related]
18. Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3.
Tracht J; Zhang K; Peker D
J Histochem Cytochem; 2017 Jul; 65(7):399-405. PubMed ID: 28651471
[TBL] [Abstract][Full Text] [Related]
19. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.
Bertucci F; Finetti P; Roche H; Le Doussal JM; Marisa L; Martin AL; Lacroix-Triki M; Blanc-Fournier C; Jacquemier J; Peyro-Saint-Paul H; Viens P; Sotiriou C; Birnbaum D; Penault-Llorca F
Ann Oncol; 2013 Mar; 24(3):625-32. PubMed ID: 23117074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
